4 Nov 2013 - 4:30pm to 5:30pm
Nurses everywhere know the drill: “Tell me how bad your pain is on a scale of 1 to 10, where 10 is the worst pain you’ve ever experienced.” Linda Bartoshuk wouldn’t use such a poor question to make decisions about pain medication. Bartoshuk studies the senses, especially taste, and she made her mark with research revealing why the experience of taste varies across individuals. Now she’s trying to fix the way scientists measure perception.
4 Nov 2013 - 3:00pm to 3:45pm
Climate scientists have been watching Greenland with alarm in recent years as its massive glaciers melt, crack and break off, losing ice at a rate that has doubled in the past 10 years. Ellen Martin and her collaborator Jon Martin are spending summers capturing a geochemical record of Greenland’s change, hoping to use this natural laboratory to inform paleoclimate studies. Ellen Martin studies the global carbon cycle by analyzing isotopic signatures of continental weathering.
4 Nov 2013 - 1:45pm to 2:30pm
Horticulture and Nutrition
What will the strawberry field, grocery store, florist’s greenhouse and space station of the future have in common? In Kevin Folta’s vision, they’ll all have automatic lighting systems and reflective surfaces that use varying colors of light to fine-tune nutrition, flavor and many other attributes in plants. Since the dawn of photosynthesis, many aspects of the lives of plants have been managed by photoreceptor chemistry.
4 Nov 2013 - 1:00pm to 1:45pm
Burning tanker trains, oil sands, fracking, pipeline wars. A quarter-century after the G20 nations agreed on a target for reducing atmospheric carbon dioxide, local and regional ecological crises dominate the debate over energy and environment. Mark Jaccard sees international economic and political systems as paralyzed by a sort of mass delusion about global carbon. Jaccard, a contributor to the early IPCC reports, will offer an economist's perspective on North American energy controversies as well as the IPCC reports coming out this fall.
4 Nov 2013 - 11:15am to 12:00pm
How close is medicine to a world in which your treatment for hypertension, coronary artery disease or pain is fine-tuned to your genotype? Weaving a path through the thorny issues surrounding “personalized medicine,” Julie Johnson and her colleagues are now showing that a genotype-driven approach to drug dosing can work. An example is the blood thinner warfarin, where the therapeutic daily dose can be anywhere from 1 to 20 milligrams, and patients must have frequent blood tests to prevent dangerous bleeding and strokes.